RxDoctor Payments DataLook up a doctor →

Jennifer Toh, MD

Allergy & Immunology · New York, NYNPI 1013206085

Payments from drug & device makers

$24,966in general payments, 2019–2025

Across 790 payments — averaging $31.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$4K
  • AstraZeneca$3K
  • ARS Pharmaceuticals Operations, Inc.$3K
  • Blueprint Medicines Corporation$2K
  • Genentech USA, Inc.$2K
  • Optinose US, Inc.$2K
  • plus $9K from 37 others

What the payments were for

  • Consulting fees$4,70619%
  • Speaking & faculty fees$4,08816%
  • Travel & lodging$2161%
  • Food & beverage$15,93564%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,966 in reported general payments places this provider in the 80th percentile of 320 allergy & immunology providers in New York.

See all allergy & immunology providers in New York

Medicare billing

Part B allowed, 2024
$70,063
Medicare patients
122
Services billed
6,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab28$108,522
Dupixent SyringeDupilumab25$95,606
XolairOmalizumab24$74,389
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$40,928
Epinephrine73$17,412
Breo ElliptaFluticasone/Vilanterol37$14,496
Cromolyn Sodium32$6,041
Azelastine Hcl253$3,792
Ipratropium Bromide50$1,754
Fluticasone Propionate200$1,615
Albuterol Sulfate HfaAlbuterol Sulfate43$1,142
Montelukast Sodium40$394
Levocetirizine Dihydrochloride24$260
Famotidine20$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$99$74,38924 claims
GSKTrelegy Ellipta, Breo Ellipta$1,799$55,42487 claims
Hikma Pharmaceuticals USAEpinephrine$167$17,41273 claims
Cycle Pharmaceuticals IncCromolyn Sodium$24$6,04132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 320 allergy & immunology providers in New York.

Other allergy & immunology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →